Zacks Research Expects Lower Earnings for Editas Medicine

Editas Medicine, Inc. (NASDAQ:EDIT) – Analysts at Zacks Research dropped their Q2 2026 earnings estimates for Editas Medicine in a report released on Monday, March 23rd. Zacks Research analyst Team now anticipates that the company will earn ($0.34) per share for the quarter, down from their prior forecast of ($0.33). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine’s Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.36) EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a report on Wednesday, January 21st. Robert W. Baird set a $6.00 target price on shares of Editas Medicine in a research note on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Monday, March 9th. Chardan Capital restated a “buy” rating and set a $3.50 price target on shares of Editas Medicine in a research report on Monday, March 9th. Finally, JonesTrading raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $5.30.

Editas Medicine Stock Up 3.1%

Shares of EDIT opened at $2.32 on Wednesday. The company has a market capitalization of $227.06 million, a price-to-earnings ratio of -1.23 and a beta of 2.16. Editas Medicine has a 52 week low of $0.91 and a 52 week high of $4.54. The stock’s 50-day moving average price is $2.09 and its 200-day moving average price is $2.56.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.21. The company had revenue of $24.74 million for the quarter, compared to the consensus estimate of $8.77 million. Editas Medicine had a negative return on equity of 389.73% and a negative net margin of 395.02%.

Institutional Trading of Editas Medicine

Large investors have recently bought and sold shares of the business. Captrust Financial Advisors purchased a new position in Editas Medicine in the 2nd quarter worth approximately $26,000. StoneX Group Inc. purchased a new stake in shares of Editas Medicine in the fourth quarter valued at approximately $33,000. Victory Capital Management Inc. acquired a new stake in shares of Editas Medicine in the third quarter valued at approximately $36,000. Sei Investments Co. acquired a new stake in shares of Editas Medicine in the third quarter valued at approximately $46,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in Editas Medicine during the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 71.90% of the company’s stock.

More Editas Medicine News

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Zacks raised several forward estimates, including Q4 2026 (from -$0.37 to -$0.34), Q3 2026 (from -$0.36 to -$0.35), FY2026 (from -$1.41 to -$1.38) and FY2027 (from -$1.37 to -$1.36) — these revisions reduce expected future losses and may support the stock. Source
• Positive Sentiment: Zacks also raised near-term quarterly estimates for Q1 2027 (from -$0.36 to -$0.35) and Q2 2027 (from -$0.35 to -$0.34), which signals modest model improvement into 2027. Source
• Neutral Sentiment: Zacks published a new FY2028 EPS projection of -$1.34 for Editas; as a first-look estimate this provides a baseline but limited immediate market impact until detail or conviction increases. Source
• Neutral Sentiment: Multiple short-interest updates reported a “significant increase” but show zero shares and NaN changes in the data — the figures look erroneous/ambiguous, so short-interest-driven pressure is unclear for now. Traders should treat these reports cautiously. Source
• Negative Sentiment: Zacks trimmed Q2 2026 EPS (from -$0.33 to -$0.34) and Q4 2027 EPS (from -$0.32 to -$0.33) in separate notes — small but downward adjustments that marginally increase near-term expected losses. Source

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.